204 related articles for article (PubMed ID: 15320785)
21. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
Adgey AA
Am Heart J; 1998 Apr; 135(4):S43-55. PubMed ID: 9539495
[TBL] [Abstract][Full Text] [Related]
22. Emergency coronary artery bypass surgery in the era of glycoprotein IIb/IIIa receptor antagonist use.
Pang JT; Fort S; Della Siega A; Cohen EA
J Card Surg; 2002; 17(5):425-31. PubMed ID: 12630543
[TBL] [Abstract][Full Text] [Related]
23. IIb's are not IIb's.
Kereiakes DJ; Runyon JP; Broderick TM; Shimshak TM
Am J Cardiol; 2000 Apr; 85(8A):23C-31C. PubMed ID: 10793177
[TBL] [Abstract][Full Text] [Related]
24. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective.
Tcheng JE
Am J Cardiol; 1996 Aug; 78(3A):35-40. PubMed ID: 8751845
[TBL] [Abstract][Full Text] [Related]
25. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
[TBL] [Abstract][Full Text] [Related]
26. [GPIIb-IIIa inhibitors].
Nurden P
Transfus Clin Biol; 2001 Apr; 8(2):114-22. PubMed ID: 11386043
[TBL] [Abstract][Full Text] [Related]
27. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
Marciniak SJ; Jordan RE; Mascelli MA
Thromb Haemost; 2001 Mar; 85(3):539-43. PubMed ID: 11307828
[TBL] [Abstract][Full Text] [Related]
28. Current issues with glycoprotein IIb-IIIa antagonists.
Schneider DJ
Curr Drug Targets; 2011 Nov; 12(12):1813-20. PubMed ID: 21718238
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: potential contributing mechanism of benefit in acute coronary syndromes.
Li Y; Spencer FA; Ball S; Becker RC
J Thromb Thrombolysis; 2000 Aug; 10(1):69-76. PubMed ID: 10947916
[TBL] [Abstract][Full Text] [Related]
30. Deaths associated with platelet glycoprotein IIb/IIIa inhibitor treatment.
Brown DL
Heart; 2003 May; 89(5):535-7. PubMed ID: 12695459
[TBL] [Abstract][Full Text] [Related]
31. Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation.
Frelinger AL; Furman MI; Krueger LA; Barnard MR; Michelson AD
Circulation; 2001 Sep; 104(12):1374-9. PubMed ID: 11560852
[TBL] [Abstract][Full Text] [Related]
32. Platelet glycoprotein IIb/IIIa receptor inhibitors in ischemic heart disease.
Lefkovits J; Topol EJ
Curr Opin Cardiol; 1995 Jul; 10(4):420-6. PubMed ID: 7549085
[TBL] [Abstract][Full Text] [Related]
33. Comparative studies of a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, and abciximab on in vitro antiplatelet effect and binding properties.
Suzuki K; Sato K; Kamohara M; Kaku S; Kawasaki T; Yano S; Iizumi Y
Biol Pharm Bull; 2002 Aug; 25(8):1006-12. PubMed ID: 12186399
[TBL] [Abstract][Full Text] [Related]
34. Therapeutics of platelet glycoprotein IIb/IIIa receptor antagonism.
Gowda RM; Khan IA; Vasavada BC; Sacchi TJ
Am J Ther; 2004; 11(4):302-7. PubMed ID: 15266223
[TBL] [Abstract][Full Text] [Related]
35. Intravenous glycoprotein IIb/IIIa antagonists: their benefits, problems and future developments.
Curtin R
Curr Pharm Des; 2004; 10(14):1577-85. PubMed ID: 15134556
[TBL] [Abstract][Full Text] [Related]
36. Lotrafiban: an oral platelet glycoprotein IIb/IIIa blocker.
Liu F; Craft RM; Morris SA; Carroll RC
Expert Opin Investig Drugs; 2000 Nov; 9(11):2673-87. PubMed ID: 11060829
[TBL] [Abstract][Full Text] [Related]
37. [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
Auer J; Berent R; Lassnig E; Weber T; Maurer E; Eber B
Herz; 2003 Aug; 28(5):393-403. PubMed ID: 12928738
[TBL] [Abstract][Full Text] [Related]
38. Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists.
Quinn M; Deering A; Stewart M; Cox D; Foley B; Fitzgerald D
Circulation; 1999 May; 99(17):2231-8. PubMed ID: 10226086
[TBL] [Abstract][Full Text] [Related]
39. Clinical pharmacology of eptifibatide.
Phillips DR; Scarborough RM
Am J Cardiol; 1997 Aug; 80(4A):11B-20B. PubMed ID: 9291241
[TBL] [Abstract][Full Text] [Related]
40. Minimizing bleeding complications of percutaneous coronary intervention and glycoprotein IIb-IIIa antiplatelet therapy.
Juran NB
Am Heart J; 1999 Oct; 138(4 Pt 2):297-306. PubMed ID: 10502235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
